Journal of Clinical Oncology

Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer

Investigating Racial and Ethnic Disparities Along the Care Cascade for Older Adults Newly Diagnosed With Metastatic Cancer

US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting

PURPOSE On September 17, 2024, the US Food and Drug Administration (FDA) approved ribociclib in combination with an aromatase inhibitor (AI) for the adjuvant treatment of adults wi...

Acknowledgment of Reviewers 2025

Treat the Tumor, Spare the Esophagus: The Case for Organ Preservation in Locally Advanced Esophageal/Gastroesophageal Junction Cancer

Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer

PURPOSE Use of chemotherapy at the end of life (EOL) is discouraged, but evidence to guide decisions on the use of novel systemic anticancer treatment (SACT) agents is lacking. We examined...

Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the...

Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer”

Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial

PURPOSE To determine the benefit, measured as complete removal of a tumor so that no tumor cells are detectable during histopathologic examination of the resection margin (R0 resec...

Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence

Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

Divarasib (GDC-6036), an oral, highly potent and selective next-generation KRAS G12C inhibitor, has demonstrated a manageable safety profile and promising antitumor activity in patients with advanced...

Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers

PURPOSE This study evaluated racial and ethnic disparities along the treatment cascade for Medicare fee-for-service patients with metastatic breast, colorectal, lung, and prostate cancers...

CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer